首页|1984例HIV/AIDS患者抗病毒治疗后的死亡影响因素及列线图预测模型的构建

1984例HIV/AIDS患者抗病毒治疗后的死亡影响因素及列线图预测模型的构建

扫码查看
目的 分析重庆市荣昌区HIV/AIDS患者接受抗病毒治疗后的死亡风险因素,并构建预测其死亡风险的列线图模型,为识别、干预高危预后人群提供参考依据。方法 选取2005-2022年在重庆市荣昌区首次接受抗病毒治疗且年龄≥15岁的1 984例HIV/AIDS患者,利用Log-Rank检验比较不同组别患者生存时间的差异,Cox回归进行多因素分析筛选出治疗患者死亡风险因素,构建列线图模型。结果 多因素Cox回归分析显示,男性死亡风险是女性的1。915倍(95%CI:1。142~3。211,P=0。014),开始治疗时≥50岁死亡风险是<50 岁的 2。185 倍(95%CI:1。367~3。493,P=0。001),注射吸毒死亡风险是异性性传播的2。834倍(95%CI:1。395~5。755,P=0。004)、被动检测死亡风险是主动检测的1。909倍(95%CI:1。009~3。613,P=0。047);确诊至开始治疗时间间隔≥1月死亡风险是<1月的1。683倍(95%CI:1,063~2。667,P=0。027),基线 CD4+T 淋巴细胞计数<200 个/μl 死亡风险是≥200 个/μl 的 4。163 倍(95%CI:2。569~6。746,P<0。001);初始治疗方案中,含奈韦拉平死亡风险是含依非伟伦的1。806倍(95%CI:1。124~2。903,P=0。015),含克力芝死亡风险是含依非伟伦的3。293倍(95%CI:1。727~6。280,P<0。001);漏服药物死亡风险是没有漏服药物的2。333倍(95%CI:1。474~3。693,P<0。001)。构建列线图预测模型的校验C-index为0。797(95%CI:0。753~0。841)。受试者工作特征曲线显示5年、10年死亡预测的曲线下面积分别为0。786、0。663。5年、10年存活率的校准曲线均与标准曲线贴合。在预测5年存活率时,阈概率0。04~0。42或预测10年存活率时,阈概率0。05~0。75,预测模型的临床获益率更高。结论 初步构建的列线图模型预测能力良好,可为治疗预后高危人群的精准早识别、早干预提供参考价值。
Influencing factors of survival after antiviral therapy in 1984 HIV/AIDS patients and the construction of nomogram prediction model
Objective To analyze the influencing factors of the survival of HIV/AIDS patients after receiving antiviral therapy in Rongchang District of Chongqing,and a nomogram prediction model was constructed to predict their mortality risk,so as to provide reference for the identification and intervention of high risk groups with treatment prognosis.Methods A total of 1 984 HIV/AIDS patients aged≥15 years who received antiretroviral therapy for the first time in Rongchang District,Chongqing,China in 2005-2022 were selected,the differences in survival time of different groups were compared by using the Log-Rank test in Kaplan-Meier,the independent risk factors for death were screened out by multivariate Cox regression analysis to construct a nomogram model.Results Multivariate Cox regression analysis showed that the risk of death in the male group was 1.915 times higher than that in the female group(95%CI:1.142-3.211,P=0.014).At the beginning of treatment,the risk of death in the ≥ 50-year-old group was 2.185 times higher than that in the<50-year-old group(95%CI:1.367-3.493,P=0.001),the mortality risk of injecting drug abuse was 2.834 times higher than that of heterosexual transmission(95%CI:1.395-5.755,P=0.004),the mortality risk in the passive detection group was 1.909 times that of the active detection group(95%CI:1.009-3.613,P=0.047).In terms of the interval between diagnosis and treatment,the risk of death in the ≥1-month group was 1.683 times higher than that in the<1-month group(95%CI:1.063-2.667,P=0.027),and the risk of death in baseline CD4+T cell count<200 cells/μl was 4.163 times higher than that of ≥200 cells/μl(95%CI:2.569-6.746,P<0.001),In the initial treatment regimen,the risk of death in the nevirapine-containing group was 1.806 times higher than that in the efavirenz-containing group(95%CI:1.124-2.903,P=0.015),and the mortality risk of the lopinavir and ritonavir-containing group was 3.293 times higher than that of the efavirenz-containing group(95%CI:1.727-6.280,P<0.001),and the mortality risk in the missed drug group was 2.333 times higher than that in the non-missed drug group(1.474-3.693,P<0.001).The C-index of the nomogram prediction model was 0.797(95%CI:0.753-0.841),and the area under the curve of 5-year and 10-year death prediction was 0.786 and 0.663,respectively.The calibration curves for the 5-year and 10-year survival rates closely matched the standard curve.When predicting the 5-year survival rate,the threshold probability ranged from 0.04 to 0.42,and for predicting the 10-year survival rate,the threshold probability ranged from 0.05 to 0.75,indicating a higher clinical benefit rate for the prediction model.Conclusion The preliminarily constructed nomogram model has good prediction ability,which can provide reference value for accurate early identification and early intervention of high risk groups with treatment prognosis.

Acquired immunodeficiency syndromeAntiretroviral therapySurvival analysisNomogram

朱勇、刘代强、谢加伟、李玲、贺学俊、邱建平、罗茂烨、郭彦玲

展开 >

重庆市荣昌区疾病预防控制中心,重庆 402460

重庆市荣昌区人民医院

艾滋病 抗逆转录病毒治疗 生存分析 列线图

2024

中国国境卫生检疫杂志
中国质检报刊社

中国国境卫生检疫杂志

CSTPCD
影响因子:0.415
ISSN:1004-9770
年,卷(期):2024.47(6)